Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vesatolimod

- PMLiVE

Gilead drives NASH development with insitro collaboration

Announcement comes days after Novo Nordisk deal

- PMLiVE

Dovato approval key for Glaxo in HIV treatment

First single tablet for treatment-naïve patients

- PMLiVE

Gilead and Galapagos close in on filing for Xeljanz rival

Belgian biotech gearing up for first approval

- PMLiVE

GSK, J&J say monthly injection keeps HIV controlled

The once every four-week treatment could free those from taking daily pills

- PMLiVE

Riva leaves Gilead to head Glenmark’s innovation spin-off

Company has own bispecific antibody platform

- PMLiVE

Gilead lead NASH drug flunks phase 3 test

Analysts suspect the setback could prompt Gilead to license other candidates

- PMLiVE

Gilead awaits CEO and readouts to revive fortunes

NASH and oral RA drugs set for crucial readouts

- PMLiVE

CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

Novartis agrees pricing deal with NHS England

- PMLiVE

Roche’s O’Day swaps big pharma for big biotech

Move to Gilead enforces reshuffle at neighbours Genentech

- PMLiVE

MSD claims EU approval for two HIV products

Company battles back against dominant Gilead and GSK

- PMLiVE

Gilead NASH drug clears mid-stage trial, but rivals are looming

Positive results to challenge Intercept in emerging disease area

- PMLiVE

GSK’s says depot HIV injection works over three years

The injection could rival Gilead’s single-tablet therapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links